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Objective: The National Audit of Thrombolysis for Acute Leg Ischemia (NATALI) database is a consecutive series of
patients who underwent intra-arterial thrombolysis to treat acute leg ischemia in one of 11 centers in the United
Kingdom. The purpose of the study was to analyze the factors associated with outcome after 30 days.
Methods: The data were collected over 10 years on standard pro formas, and registration was completed at the end of 1999.
Since then, data from each unit have been verified and missing data included when available. Univariate and multivariate
analyses were performed, with the outcomes of amputation-free survival (AFS), amputation with survival, and death.
Results: A total of 1133 thrombolytic events were included. Outcome results at 30 days for the entire group were AFS,
852 (75.2%); amputation, 141 (12.4%); and death, 140 (12.4%). Results for the entire group improved from the first half
of the database, when AFS ranged from 65% to 75%, to almost 80% for the last few years of the study, although this was
not statistically significant. Preintervention factors associated with lower AFS at multivariate analysis included diabetes
(P .002), increasing age (P < .001), short-duration ischemia (P .027), Fontaine grade (P .001), and ischemia with
neurosensory deficit (P  .004). AFS was improved in patients receiving warfarin sodium at the time of the arterial
occlusion (P  .04). Mortality was higher in women (P  .006) and in older patients (P < .001), and in patients with
native vessel occlusion (P < .001), emboli (P  .02), or a history of ischemic heart disease (P < .001). Amputation risk
was greatest in younger men (P < .001) and in patients with more severe ischemia (P  .02), graft occlusion (P < .001),
or native vessel thrombotic occlusion (P  .02).
Conclusion: Experienced surgeons and radiologists can achieve an AFS of about 80% in selected patients with acute leg
ischemia. Information from the NATALI database can be used in selection of an appropriate intervention in the
individual patient. (J Vasc Surg 2004;39:1018-25.)Thrombolytic therapy was developed as a means to
open arteries or veins occluded by fresh thrombus. For
patients with acute leg ischemia it has become an alternative
to surgical treatment, such as embolectomy or vascular
reconstruction. Since 1974, when Dotter et al1 first de-
scribed the intra-arterial technique, vascular surgeons and
radiologists have explored methods and indications for
local thrombolysis of acute leg ischemia. A large literature
exists, including open and randomized trials, yet the exact
role of lysis remains elusive.2 The aim of the present study
was to use a large prospective database collected over a
decade to explore the indications for thrombolysis in acute
leg ischemia.
The Thrombolysis Study Group (TSG) was formed in
1990 by a group of surgeons and radiologists from various
hospitals in the United Kingdom who wished to conduct
research into peripheral thrombolysis. The group met and
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acute leg ischemia, and agreed to collect data, using stan-
dard forms, in a computer database, The National Audit of
Thrombolysis for Acute Leg Ischemia (NATALI).3 The
group has previously published information from the data-
base concerning various methods of lysis, the effects of
aspirin on thrombolysis, and the treatment of acute-onset
claudication.4-6
The database was completed at the end of 2000, the
year in which more than 1000 episodes of thrombolysis had
been recorded. Since then an extensive program of data
verification has been undertaken for the current statistical
analysis.
METHODS
In the 10 years that data have been collected by the
TSG, 43 vascular surgeons and radiologists from 14 hospi-
tals in the United Kingdom have contributed. Both district
hospitals and teaching hospitals are included; a full list of
participants is presented in the Appendix. Participants
agreed to collect data on consecutive patients undergoing
intra-arterial lysis to treat acute leg ischemia, defined as
“sudden deterioration in the circulation to a leg, which has
previously been adequate at rest.” Patients treated conser-
vatively and those who underwent primary surgery were
excluded. Some centers joined after 1990, and not all
centers collected data continuously to the end of the de-
cade. Data were returned to the NATALI database coordi-
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received satellite computer links) or on paper, to be entered
centrally by the database coordinator. Most of the data
were collected contemporaneously, but some missing in-
formation was entered retrospectively during verification.
Results were returned annually to participating centers as
part of the audit process. Each center received copies of
their own outcome results, together with results from the
group overall, for comparison. National meetings were
held annually to discuss these results and to define projects
for further study.
It was agreed to close the database after 1000 episodes
of intra-arterial lysis had been collected, and this was
achieved in 2000. Final data entry was agreed to be on
December 31, 2000. There followed an extensive program
of verification. The NATALI database coordinator visited
each hospital with an independent observer (consultant
vascular nurse). Radiology department records, vascular
databases, and any other available sources were checked to
ensure that consecutive patients had been included. Miss-
ing data and patients captured retrospectively were in-
cluded and entered into the database. A sample of approx-
imately 10% of the completed records at each hospital was
reviewed to determine whether there were any significant
data mismatches. Overall, fewer than 10% of the sampled
records were changed or upgraded as a result of the verifi-
Fig 1. Recruitment to the National Audit of Thromb
participating centers in the final clinical analysis.cation process. Most of the changes were the result of
missing, rather than inaccurate, data.
The present analysis was undertaken to determine
whether preoperative patient-related factors could be used
to predict outcome. An analysis of outcomes related to
methods of thrombolysis and specifics of the thrombolytic
regimens are the subject of a separate analysis. To be
included in the current analysis, centers had to have sub-
mitted consecutive patients for several years, to have en-
tered at least 50 episodes, and to have agreed to the
verification process. Eleven of the 14 centers fulfilled these
criteria. Recruitment details to the NATALI database are
shown in Fig 1. Recruitment was maximal in the mid-
1990s, then trailed off over the last few years of the study.
The principal outcomes analyzed were defined 30 days after
treatment: amputation-free survival (AFS), major amputa-
tion with survival (amputation), and death, including death
after amputation. Initially, univariate analysis (cross-
tabulation with 2 tests) was performed with AFS as the
primary end point. Significant variables were then subjected
to multivariate analysis with binary logistic regression. Fi-
nally, patients with the end points of amputation or death
were compared, again with binary logistic regression, to
determine the additional risk factors for these categories.
Significance was accepted at P .005. All statistical analysis
for Acute Leg Ischemia database by year for the 11olysis
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RESULTS
The present analysis included verified data from 11
centers that fulfilled the criteria for inclusion and collected
information on 1147 episodes of intra-arterial thromboly-
sis. Outcome data were lacking in 14 episodes, which were
therefore excluded, leaving 1133 episodes for analysis.
There were 631 men and 380 women, mean age 68.5 years
(range, 17-97 years). All had acute leg ischemia as defined,
and 11% of patients had more than one episode in the
database. For purposes of analysis, each episode was treated
separately. Patient risk factors identified included diabetes
(n 172, 15.2%), ischemic heart disease (n 353, 31.1%),
known peripheral vascular disease (n  678, 59.8%), and
previous stroke (n  91, 8%). At admission 322 patients
(28.4%) were taking aspirin and 118 (10.4%) were receiving
oral anticoagulation therapy with warfarin sodium.
Symptoms of ischemia (known in 1132 episodes) were
present for less than 8 hours in 288 episodes (25.4%), 8 to
48 hours in 336 episodes (29.6%), 48 hours to 1 week in
231 episodes (20.4%), and more than 1 week in 277
episodes (24.4%). Severity of ischemia (known in 1078
episodes), as defined according to Fontaine grade, was
grade II in 214 patients (19.8%), grade III in 746 patients
(69.2%), and grade IV in 104 patients (9.6%). At presenta-
tion 519 patients (48.5%) had acute critical ischemia with
complete or partial neurosensory deficit, and 556 patients
(51.5%) had subacute critical ischemia, without any evi-
dence of neurosensory loss.7 These data were recorded in
1069 episodes.
All patients underwent local catheter-directed intra-
arterial thrombolytic therapy. Some early patients received
streptokinase (n  59), but since 1994 all received tissue
plasminogen activator. Urokinase was not widely available
in the United Kingdom and was more expensive than tissue
plasminogen activator, and hence was used in only 23
episodes. A number of thrombolytic techniques were used,
including standard low-dose infusion, initial high-dose bo-
lus infusion,8 and pulsed-spray thrombolysis.9 Initial out-
come at the end of the infusion (Table I) was complete lysis
in 516 episodes (45.5%), partial (clinically useful) lysis in
314 episodes (27.7%), lysis but no runoff in 141 episodes
(12.4%), and no lysis in 162 episodes (14.3%).
After 30 days the final clinical outcome in the series
overall was AFS in 852 patients (75.2%), amputation in 141
patients (12.4%), and death in 140 patients (12.4%). Re-
sults for the group overall improved from the early part of
the study (AFS, 65%-75% in 1990-1993) to AFS of almost
80% in the last few years, although this was not statistically
significant (Fig 2).
The outcome was complicated after 299 episodes of
intra-arterial thrombolysis (complete data in 1108 epi-
sodes). Major hemorrhage that required transfusion or
operation was seen after 87 episodes (7.85%), of which five
were fatal; minor hemorrhage occurred after 70 episodes
(6.3%) episodes. Stroke occurred in 26 patients (2.3%),which proved fatal in 20 patients. Other significant compli-
cations included distal embolization in 27 patients (2.4%),
reperfusion injury in 20 patients (1.8%), pericatheter
thrombosis in 9 patients (0.8%), and allergy in a single
patient. The cause of death was recorded in 76 of 140
episodes (54%). The commonest known causes were myo-
cardial infarction or failure (n  24), stroke (n  20),
pneumonia (n  7), and renal failure (n  6). Only five
patients died of hemorrhage. There was no systematic
effort to verify cause of death; the cause documented on the
NATALI form by the local clinician was accepted. This may
have included autopsy data, but it may simply have been a
clinical diagnosis.
Univariate and multivariate analyses. Preoperative
factors that could be predictive of outcome were subjected
to univariate analysis, with the outcome being AFS at 30
days (Table II). Preoperative patient-related factors that
affected outcome included age, diabetes mellitus, and use
of warfarin before the onset of acute ischaemia. AFS dete-
riorated progressively with age, from 87% for episodes in
patients younger than 60 years to 65% for episodes in those
older than 80 years (P .001). AFS was reduced to 66% in
the 172 episodes in patients with diabetes (P  .003). In
118 episodes the patient was taking warfarin at the time of
onset of acute ischemia; AFS was improved to 83% in this
group (P  .04).
The duration of leg ischemia also affected outcome
significantly; the shorter the duration the higher the risk for
death or amputation (Table III). AFS improved from 69%
for ischemia of less than 8 hours’ duration to 80% for
ischemia for longer than 1 week (P  .02). The severity of
leg ischemia had a marked effect on outcome. AFS dimin-
ished with increasing Fontaine grade, and was also signifi-
cantly related to the presence of a neurosensory deficit. AFS
was 80% in episodes with no deficit, and decreased to 56%
when complete neurosensory deficit was reported (P 
.001). There was no significant difference in the rate of AFS
when graft and native vessel occlusions were compared, nor
Table I. Outcome definitions after thrombolysis used in
NATALI database
Initial result
Complete lysis: Clearance of occluded vessel, with restoration of
flow to runoff and restoration of peripheral pulses.
Partial lysis: Partial clearance of thrombus that relieved rest pain
or improved ankle-brachial pressure index by at least 0.2; or
partial clearance that enabled a smaller operation to be
undertaken than was possible before lysis or that enabled a
procedure to be performed when prior to therapy none was
possible.
Lysis, but no runoff: Successful lysis of acute thrombus (usually an
occluded bypass graft), but without establishing runoff flow
into major distal vessels.
No lysis: No improvement after lysis, or deterioration in state of
limb perfusion.
Data from Braithwaite BD, Ritchie AWS, Earnshaw JJ. NATALI: a model
for national computer databases in the investigation of new therapeutic
techniques. J R Soc Med 1995;88:511-5.
NATALI, National Audit of Thrombolysis for Acute Leg Ischemia.
is to t
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and not surprising, AFS was 91% after successful intra-
arterial lysis, and decreased to 39% when an occluded graft
could be reopened, but without evidence of distal runoff.
At multivariate analysis the pretreatment factors that
remained significantly related to AFS were age (P  .001),
diabetes (P  .002), duration of ischemia (P  .027),
Fontaine grade (P .001), and presence of a neurosensory
deficit (P  .004).
In a second analysis, data for patients who died were
compared with data for those who required amputation but
survived, again using multivariate analysis (Table II). Fac-
tors that increased the risk for death included sex (women
were less likely to survive; P  .006), increasing age (P 
.001), ischemic heart disease (P  .001), native vessel
occlusion (P  .001), and occlusion caused by embolus (P
 .02). Conversely, factors that increased the risk for
amputation were male sex, younger age, increasing Fon-
taine grade (P .02), graft occlusion, and occlusion caused
by thrombosis.
DISCUSSION
It has been 30 years since intra-arterial thrombolysis
was described to treat acute leg ischemia, yet it has still to
find a clear role. Suggestions that it may replace surgery for
treatment of all acute limb ischemia have been overoptimis-
tic.10 The technique is widely used by many clinicians who
believe it has a significant role, but others have doubts.11
Whereas randomized controlled trials have not identified
an overall advantage for thrombolysis,12-14 meta-analysis
Fig 2. Thirty-day outcomes after thrombolyshas demonstrated benefit in selected patients.15,16 The
purpose of this analysis of the NATALI database was to try
to define the role of intra-arterial thrombolysis more
clearly. The strengths of the project include the size of the
database, which is larger than all the randomized trials
combined. It has also been extensively checked and veri-
fied. The results can be compared with a combined review
of lysis and surgery17 and data from the national inpatient
sample in the United States.18 It is reassuring that AFS rates
in the present database are similar to those achieved in
randomized trials.
The NATALI database is, however, limited in the in-
formation it contains. It cannot be used to examine indi-
vidual indications for thrombolysis, because patients who
underwent surgery were not included, and clinicians were
free to choose which patients received thrombolysis. All
patients had acute ischemia, though clearly in some the
situation was not critical. Indeed, the TSG has previously
published data that show a high adverse outcome rate in
patients with acute-onset claudication treated with throm-
bolysis.6 Whereas AFS may not be the most appropriate
means for assessing outcome in this group of patients, all
had borderline rest pain that required intervention, and
other end points were similar to those for other patients in
the database. From the wide variation in the duration of
ischemia recorded it is obvious that a small number of more
chronic occlusions were treated, although 75% of episodes
had been present for less than 1 week. Similarly, the data-
base gives no information about patients who underwent
surgery. Only a relatively small proportion had symptoms
reat acute leg ischemia, by year of treatment.
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with short-duration severe ischemia underwent thrombo-
embolectomy. The database does, however, include a large
number of threatened legs; almost half of the episodes
included a neurosensory deficit. The current study did not
analyze the contribution of the various radiologic tech-
niques to outcome; this will be the subject of future re-
search. Earlier analysis of the database failed to find differ-
ences in outcome among the various thrombolytic
techniques.4 Finally, even after verification there remained
data gaps; thus the numbers varied in each statistical anal-
ysis.
There is evidence that members of the TSG changed
the threshold or indication for thrombolytic therapy during
Table II. Univariate analysis of factors associated with amp
treat acute leg ischemia
Thrombolytic
events
(N  1133)
Patient factors
Sex
Female 380
Male 631
Age (y)
59 236
60-69 308
70-79 369
80 208
Diabetes 172
In-hospital dialysis 353
Peripheral vascular disease 678
Stroke 91
Aspirin 322
Warfarin 118
Leg factors
Duration
8 h 288
8-48 h 336
48 h-1 wk 231
1 wk 277
Fontaine grade (n  1078)
II 214
III 746
IV 104
Neurosensory deficit (n  1069)
None 550
Partial 428
Complete 91
Vessel
Native 655
Graft 478
Type of occlusion
Thrombus 679
Embolus 211
Unknown 243
Lysis factors
Complete 516
Clinically useful 314
Lysis but no runoff 141
No lysis 162the 10-year study.19 Recruitment to the database was max-
imal during the first half of the decade, then trailed off in
many centers. The validation exercise proved that the
change was real and not just a reduction in the number of
cases registered. This reduction could have been due to
changing enthusiasm for the project, or it could have been
because the audit process and publication of early results
focussed inclusion toward more suitable patients. Addi-
tional evidence that the latter explanation was responsible
comes from the fact that the outcome results for the TSG
overall improved over the decade of the study. Numbers for
each hospital were too small to determine whether this
improvement was seen in all or just some of the centers.
There may be a significant learning curve for the technique
ion-free survival 30 days after peripheral thrombolysis to
FS (n  852,
75%)
Death or
amputation
(n  281, 25%)
P% n %
.25
6 73 104 27
9 76 152 24
.001
6 87 30 13
2 75 76 25
9 73 100 27
5 65 73 35
4 66 58 34 .003
5 75 88 25 .95
6 76 162 24 .39
8 75 23 25 .91
1 78 71 22 .18
8 83 20 17 .04
.02
0 69 88 31
1 78 75 22
0 74 61 26
1 80 56 20
.001
8 83 36 17
5 74 191 26
3 61 41 39
.001
1 80 109 20
0 75 108 25
1 56 40 44
.11
1 73 174 27
1 78 107 22
.46
9 76 160 24
6 74 55 26
7 73 66 27 Not in analysis
.001
0 91 46 9
6 78 68 22
5 39 86 61
1 50 81 50utat
A
n
27
47
20
23
26
13
11
26
51
6
25
9
20
26
17
22
17
55
6
44
32
5
48
37
51
15
17
47
24
5
8
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could just have been due to increasing expertise in the
participating centers. There was, however, no difference in
outcomes when centers that contributed more than 100
episodes to the database were compared with those who
submitted fewer than 100 episodes.
The goal of the present study was to help clinicians
identify which factors are associated with better outcome
after thrombolysis. The best predictor of outcome is
whether the procedure is successful, but it is self-evident
that this information is not available before treatment is
started. Acute leg ischemia is complex, with multifactorial
causes and wide variation in patient status. Outcomes are
different for the patient and the limb. AFS is the ideal
composite end point, first used in the Surgery vs Throm-
bolysis for Ischemic Lower Extremity trial,13 but it ignores
that the two main adverse outcomes, amputation and
death, have different risk factors.
Previous reports have highlighted that differences in
outcome were dependent on the cause of the occlusion. In
Table III. Univariate analysis of factors associated with am
treat acute leg ischemia
Thrombolytic
events
(n  281)
Patient factors
Sex
Female 78
Male 126
Age (y)
59 27
60-69 59
70-79 73
80 54
Diabetes 38
In-hospital dialysis 70
Peripheral vascular disease 127
Stroke 21
Aspirin 58
Warfarin 16
Leg factors
Duration
8 h 65
8-48 h 64
48 h-1 wk 44
1 wk 41
Fontaine grade
II 25
III 145
IV 34
Neurosensory deficit
None 78
Partial 90
Complete 26
Vessel
Native 129
Graft 86
Type of occlusion
Thrombus 160
Embolus 55
Unknownthe Surgery vs Thrombolysis for Ischemic Lower Extremity
trial, patients with a graft occlusion had a higher chance for
successful AFS than did those with native vessel occlu-
sions13; this was also confirmed with meta-analysis.15 The
fate of reopened grafts remains dubious, inasmuch as fol-
low-up studies have shown a low rate of retained patency at
1 year.20,21 For native vessel occlusions, standard teaching
is that patients with emboli are at higher risk for death
because of associated cardiac disease, and patients with
thrombosis are at higher risk for amputation because of
poor runoff.22,23 The cause of occlusion was also a signifi-
cant factor that determined differences between amputa-
tion and death in the present study.
In the current investigation, factors that influenced
AFS were increasing age, diabetes, duration and severity of
ischemia (both Fontaine grade and presence of neurosen-
sory deficit). This information enables clinicians to build a
clinical picture of patients with acute leg ischemia unlikely
to do well with thrombolysis, who could perhaps undergo
surgery instead, although as yet there is no evidence that
tion or death 30 days after peripheral thrombolysis to
putation Death
P% n %
.006
37 49 63
57 54 43
.001
78 6 22
61 23 39
44 41 56
33 36 67
63 14 37 .11
33 47 67 .001
54 58 46 .17
43 12 57 .5
55 26 45 .44
63 6 37 .44
.67
49 33 51
45 35 55
55 20 45
56 18 44
.02
36 16 64
47 77 53
71 10 29
.89
51 38 49
51 44 49
46 14 54
.001
40 77 60
65 30 35
.02
55 72 45
36 35 64
Not in analysisputa
Am
n
29
72
21
36
32
18
24
23
69
9
32
10
32
29
24
23
9
68
24
40
46
12
52
56
88
20
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tive in these patients with severe acute ischemia is a percuta-
neous thrombectomy device, although its use is not wide-
spread in the United Kingdom. In addition, female sex,
ischemic heart disease, and embolic occlusion were associated
with higher mortality. These are also factors to take into
account when making management decisions. Acute leg isch-
emia is a common condition in elderly women, who are
already recognized as a group at high risk.24
One reason why thrombolysis is not widely used is the
perceived hazard. Clearly there are risks from local bleeding
from arterial puncture sites, but there were only five deaths
in the present database. Stroke is the most feared compli-
cation, and followed 2.3% of episodes in the NATALI
database. A previous analysis suggested that approximately
half were hemorrhagic and half were thromboembolic;
most occurred during anticoagulation after thromboly-
sis.25 In the randomized trials there was little difference in
morbidity and mortality from surgery and thrombolysis. It
is noteworthy that the rates of distal embolization and
pericatheter thrombosis were low, even though most radi-
ologists did not use heparin during thrombolysis.
It has been argued that thrombolysis has not proved
superior to surgery, and therefore should not be seen as a
standard treatment.11 Others, particularly enthusiasts, be-
lieve it is an effective treatment, with an important role in
selected patients, and that it belongs at the center of the
options available to a good vascular interventional depart-
ment. Experts have joined to produce guidelines for its use.26
All new techniques go through an enthusiast phase before
settling into mainstream practice. Thrombolytic therapy is
now widely used in many vascular radiology departments
throughout the world. Previous work has suggested this is a
cost-effective approach.27 The present research shows that
much can be learned from carefully collected databases and
randomized trials, and that experts can achieve creditable
results; the TSG achieved almost 80% AFS at the end of the
study. The past decade of research has begun to identify which
patients with acute leg ischemia will do well with thromboly-
sis, and clinicians can use this information to tailor appropriate
therapy to individual patients.
We thank Mr I. Desborough and Ms A. Cartwright for
their help and advice.
APPENDIX
The following are members of the Thrombolysis Study
Group:
Ms S. Baker (Bournemouth), Prof J. Belch (Dundee),
Prof P. R. Bell (Leicester), Dr A.-M. Belli (London), Mr
J. D. Beard (Sheffield), Mr D. C. Berridge (Leeds), Dr P.
Birch (Gloucester), Mr B. D. Braithwaite (Nottingham),
Dr T. Buckenham (London), Dr N. Chalmers (Manches-
ter), Mr N. Cheshire (London), Mr K. Dawson (London),
Prof J. Dormandy (London), Dr J. Dyett (Hull), Ms L.
Earby (Northampton), Mr J. J. Earnshaw (Gloucester), Dr
P. A. Gaines (Sheffield), Mr R. B. Galland (Reading), Mr
A. E. B. Giddings (London), Dr I. Gillespie (Edinburgh),Dr R. H. S. Gregson (Nottingham), Mr G. Hamilton
(London), Mr B. P. Heather (Gloucester), Prof B. P.
Hopkinson (Nottingham), Ms M. Ireland (Sheffield), Ms
C. Judge (London), Ms M. Kerle (London), Dr R. Ken-
drick (Northampton), Dr D. Kessell (Leeds), Dr H. Loose
(Newcastle), Mr T. Loosemore (London), Ms P. Morris
Vincent (London), Dr J. Moss (Glasgow), Dr R. Morgan
(London), Mr S. Parvin (Bournemouth), Dr A. Platts
(London), Mr D. Ratcliff (Northampton), Dr K. Reddy
(Gillingham), Ms A. Reed (Leicester), Dr B. Riddler (Ex-
eter), Dr J. Rose (Newcastle-upon-Tyne), Mr J. Thompson
(Exeter), Dr P. Torrie (Reading), Dr T. Tottle (Glouces-
ter), Dr T. Watkinson (London), Mr P. Wenham (Notting-
ham), Ms B. Whitman (Gloucester), Dr S. Whittaker (Not-
tingham), Ms L. Wilson (Newcastle), Mr J. H. N. Wolfe
(London), and Mr M. Wyatt (Newcastle).
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Available online Mar 10, 2004.MENTORED PATIENT-ORIENTED RESEARCH CAREER DEVELOPMENT AWARD
The Lifeline Foundation and the National Heart, Lung and Blood Institute (NHLBI) wish to
announce their joint sponsorship of the NHLBI Mentored Patient-Oriented Research Career Develop-
ment Award (K23), which will provide supplemental funding for vascular surgeon scientists in the early
stages of their research careers.
The purpose of the Mentored Patient-Oriented Research Career Development Award (K23) is to
support the career development of investigators who have made a commitment to focus their research
endeavors on patient-oriented research. The objectives of the Mentored Patient-Oriented Research
Career Development Award (K23) are (1) to encourage research-oriented clinicians to develop indepen-
dent research skills and gain experience in advanced methods and experimental approaches needed to
conduct patient-oriented research and (2) to increase the pool of clinical researchers who can conduct
patient-oriented studies, capitalizing on the discoveries of biomedical research and translating them to
clinical settings.
The application deadline is June 1, 2004. For more information, contact the Lifeline Foundation at
lifeline@vascularsociety.org or visit VascularWeb (http://www.vascularweb.org/).
